Kala Pharmaceuticals, a late-stage biotech developing nanoparticle therapies for ocular inflammation, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Waltham, MA-based company was founded in 2009 and plans to list on the Nasdaq under the symbol KALA. Kala Pharmaceuticals filed confidentially on September 21, 2015. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
